Intelligent bio solutions to strengthen fda 510(k) submission with new positive data demonstrating ultra-precise fingerprint sweat detection and platform resilience

Data confirms company's ability to detect trace sweat volumes at ultra-micro level system demonstrates resilience across diverse conditions new york, july 23, 2025 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) ("inbs" or the "company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful collection of new data that further reinforces the security and performance of its intelligent fingerprinting drug screening system, strengthening its fda 510(k) submission. "our ongoing dialogue with the fda throughout the 510(k) process has been constructive and forward-looking," said peter passaris, vice president of product development.
INBS Ratings Summary
INBS Quant Ranking